Results 41 to 50 of about 35,846 (211)
Journal of Enzyme Inhibition and Medicinal Chemistry, 2018 Dipeptidyl peptidase 4 (DPP-4) inhibitors are used for the treatment of type-2 diabetes mellitus. Various synthetic inhibitors have been developed to date, and plants containing natural DPP-4 inhibitors have also been identified.
Eisuke Kato +2 more
doaj +1 more source
SGLT-2 Inhibitors: A Novel Mechanism in Targeting Glycemic Control in Type 2 Diabetes Mellitus [PDF]
, 2016 OBJECTIVE: To review the chemistry, pharmacology, pharmacodynamics, pharmacokinetics, clinical efficacy, tolerability, dosing, drug interactions, and administration of canagliflozin, dapagliflozin, and empagliflozin, and comparing the benefit and risk ...
Ahmed-Sarwar, Nabila +2 more
core +2 more sources
Frontiers in Pharmacology, 2017 Background and Objectives: Limited research focuses on the risk of ischemic cerebrovascular disease associated with use of dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) in patients with type 2 diabetes mellitus in Taiwan.
Shih-Wei Lai +7 more
doaj +1 more source
Editorial – COVID-19 pandemic: is it time to learn about DPP-4/CD26? [PDF]
CellR4, 2020 The rapid spread of SARS-CoV-2, a novel coronavirus that emerged in late 2019, and the resulting COVID-19 pandemic, has been labeled as a public health emergency of international concern by the World Health Organization.
M. Maia Pinheiro +2 more
doaj +1 more source
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice [PDF]
, 2016 Diabetic patients suffer from a high rate of cardiovascular events and such risk increases with HbA1c. However, lowering HbA1c does not appear to yield the same benefit on macrovascular endpoints, as observed for microvascular endpoints. As the number of
Avogaro, Angelo +4 more
core +3 more sources
DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Journal of Diabetes Research, 2018 Objective. Several clinical studies have reported the application of dipeptidyl peptidase-4 (DPP-4) inhibitors as treatments for type 1 diabetes mellitus (T1DM).
Qixian Wang +8 more
doaj +1 more source
Cardiovascular Diabetology, 2018 Background Incretin-based therapies including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon like peptide-1 (GLP-1) receptor agonists are novel medications for type 2 diabetes management.
Ghadeer K. Dawwas +2 more
doaj +1 more source
Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients [PDF]
, 2016 Aims: Treatment with glucagon-like peptide (GLP)-1 receptor agonists or dipeptidyl peptidase (DPP)-4 inhibitors might increase gallstone formation; however, the mechanisms involved are unknown. We aimed to assess the effects of these drugs on gallbladder
Cahen, D.L. (Djuna) +9 more
core +1 more source
Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis [PDF]
Endocrinology and Metabolism, 2019 BackgroundTo investigate the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on renal outcomes in patients with type 2 diabetes.MethodsMEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched to identify randomized ...
Jae Hyun Bae +5 more
doaj +1 more source
Cardiovascular effects of the DPP-4 inhibitors
Diabetes and Vascular Disease Research, 2012 Type 2 Diabetes continues to rise in prevalence throughout the globe, and cardiovascular diseases remain the most common cause of morbidity and mortality among patients. Dipeptidyl-peptidase-4 (DPP-4) inhibitors are a newer class of oral anti-hyperglycemic agents whose effect is mediated through the incretin hormones, GLP-1 and GIP. In this review, we
Tessey, Jose, Silvio E, Inzucchi
openaire +2 more sources